Open Access

Table 3

Characteristics of patients during follow-up according to hemoglobin type.

HbAA HbAC HbAS HbCC HbSC HbSS
Patients followed-up from day 3 onward (n) 646 60 47 5 7 5
 Positive parasitemia on day 3 n (%) 3 (0.5) 1 (1.7) 0 (00) 0 (00) 0 (00) 0 (00)
 Early treatment failure (ETF) n (%) 0 (00) 0 (00) 0 (00) 0 (00) 0 (00) 0 (00)
 Late clinical failure (LCF) n (%) 33 (5.1) 4 (6.7) 1 (2.1) 1 (20) 0 (00) 0 (00)
 Late parasitological failure (LPF) n (%) 7 (1.1) 0 (00) 0 (00) 0 (00) 0 (00) 0 (00)
 Recrudescence (defined on PCR typing) n (%) 0 (00) 0 (00) 0 (00) 0 (00) 0 (00) 0 (00)
 New infection n (%) 40 (6.2) 4 (6.7) 1 (2.1) 1 (20) 0 (00) 0 (00)
 Adequate clinic parasitological response (ACPR) (%) 100 100 100 100 100 100
p-values HbAA vs. HbAC HbAA vs. HbAS HbAA vs. HbCC HbAA vs. HbSC HbAA vs. HbSS

 Positive parasitemia on day 3 n (%) 0.29 1 1 1 1
 Early treatment failure (ETF) n (%) 1 1 1 1 1
 Late clinical failure (LCF) n (%) 0.54 0.72 0.23 1 1
 Late parasitological failure (LPF) n (%) 1 1 1 1 1
 Recrudescence (defined on PCR typing) n (%) 1 1 1 1 1
 New infection n (%) 0.78 0.35 0.27 1 1

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.